Insider · CIK 0001353838
Ronald C Keating
director
Files at NPO (Enpro Inc.), HAYW (Hayward Holdings, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2025 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +2 | $217.89 | $461 | 3,774 | Sep 18, 2025 |
| Jun 30, 2025 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +131 | $191.55 | $25k | 3,771 | Jul 1, 2025 |
| Jun 18, 2025 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +2 | $185.86 | $420 | 3,641 | Jun 20, 2025 |
| May 22, 2025 | HAYW Hayward Holdings, Inc. | AGrant or award Common Stock | +9,462 | $0.00 | $0 | 42,758 | May 27, 2025 |
| May 2, 2025 | HAYW Hayward Holdings, Inc. | AGrant or award Common Stock | +3,296 | $0.00 | $0 | 33,296 | May 6, 2025 |
| Mar 31, 2025 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +155 | $161.79 | $25k | 3,639 | Apr 1, 2025 |
| Mar 19, 2025 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +2 | $175.76 | $372 | 3,484 | Mar 20, 2025 |
| Feb 13, 2025 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +685 | $182.27 | $125k | 3,482 | Feb 13, 2025 |
| Dec 31, 2024 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +145 | $172.45 | $25k | 2,797 | Jan 2, 2025 |
| Dec 18, 2024 | NPO Enpro Inc. | AGrant or award Phantom Stockderivative | +2 | $175.86 | $316 | 2,652 | Dec 19, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.